A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

NCT05567185 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms
Receptors, Fibroblast Growth Factor

Interventions

DRUG: Erdafitinib Intravesical Delivery System

Sponsor

Janssen Pharmaceutical K.K.